- Home
- CANF vs FCUV Comparison
CANF vs FCUV Comparison
Compare CANF & FCUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- FCUV
- Stock Information
- Founded
- CANF 1994
- FCUV 2012
- Country
- CANF Israel
- FCUV United States
- Employees
- CANF N/A
- FCUV N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- FCUV Industrial Machinery/Components
- Sector
- CANF Health Care
- FCUV Industrials
- Exchange
- CANF Nasdaq
- FCUV Nasdaq
- Market Cap
- CANF 14.4M
- FCUV 14.8M
- IPO Year
- CANF N/A
- FCUV N/A
- Fundamental
- Price
- CANF $2.36
- FCUV $0.22
- Analyst Decision
- CANF Strong Buy
- FCUV
- Analyst Count
- CANF 2
- FCUV 0
- Target Price
- CANF $14.00
- FCUV N/A
- AVG Volume (30 Days)
- CANF 114.9K
- FCUV 1.1M
- Earning Date
- CANF 11-15-2024
- FCUV 11-15-2024
- Dividend Yield
- CANF N/A
- FCUV N/A
- EPS Growth
- CANF N/A
- FCUV N/A
- EPS
- CANF N/A
- FCUV N/A
- Revenue
- CANF $667,000.00
- FCUV $839,623.00
- Revenue This Year
- CANF $356.93
- FCUV N/A
- Revenue Next Year
- CANF N/A
- FCUV N/A
- P/E Ratio
- CANF N/A
- FCUV N/A
- Revenue Growth
- CANF N/A
- FCUV 43.94
- 52 Week Low
- CANF $1.81
- FCUV $0.15
- 52 Week High
- CANF $4.69
- FCUV $2.38
- Technical
- Relative Strength Index (RSI)
- CANF 60.97
- FCUV 38.52
- Support Level
- CANF $1.87
- FCUV $0.22
- Resistance Level
- CANF $2.04
- FCUV $0.29
- Average True Range (ATR)
- CANF 0.17
- FCUV 0.03
- MACD
- CANF 0.04
- FCUV -0.01
- Stochastic Oscillator
- CANF 72.06
- FCUV 6.52
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About FCUV Focus Universal Inc.
Focus Universal Inc develops and manufactures universal smart devices. Its product portfolio includes Universal Smart Instrumentation Platform, Ubiquitor, Universal Smart Controller, and Sensors. The company also supplies various air filtration systems. The Company consists of three types of operations- Focus and Focus Shenzhen (Corporate), Perfecular and Lusher (IoT Products), and AVX (IoT Installation Services). The majority of revenue is generated from IoT Installation Services. IoT Installation Services segment is an IoT installation and management company specializing in high-performance and easy-to-use audio/video, home theater, lighting control, automation, and integration.